{"entity":{"id":"2026","kind":"year","name":"2026 in oncology","aka":["2026"],"tldr":"Everything OnCo dates to 2026: 471 entries, 113 papers, 79 trials reported, 77 regulatory events and 68 landmarks. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"471 dated entries in OnCo fall in 2026: 113 papers, 79 trials reported, 77 regulatory events, 68 landmarks, 56 approvals, 27 financing rounds, 24 expected dates, 24 papers listed on people's pages, 1 company founded, 1 technology and 1 guideline change.\n\nOf those, 68 to the day, 14 to the month, 17 to the quarter and 372 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2025","2027"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2026,"events":[{"group":"approval","date":"2026","precision":"year","title":"Acalabrutinib approved in US","note":"Fixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)","from":"acalabrutinib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq approved in US","note":"Adults with haematological malignancies undergoing matched-donor haematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologi...","from":"tregzi","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Amivantamab approved in England (NICE)","note":"Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with lazertinib.","from":"amivantamab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Amivantamab approved in England (NICE)","note":"Untreated advanced non-small-cell lung cancer with an activating EGFR exon 20 insertion, with carboplatin and pemetrexed.","from":"amivantamab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"ArteraAI Breast approved in US","note":"Risk stratification in early-stage HR+/HER2- invasive breast cancer","from":"artera-ai-breast","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Atezolizumab approved in US","note":"Adjuvant muscle-invasive bladder cancer, ctDNA-positive after cystectomy","from":"atezolizumab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Aumolertinib approved in EU","note":"Aumseqa: first-line advanced NSCLC with EGFR exon 19 deletion or L858R; advanced EGFR T790M-positive NSCLC","from":"aumolertinib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Belzutifan approved in US","note":"Adjuvant clear-cell RCC with pembrolizumab","from":"belzutifan","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Bevacizumab approved in England (NICE)","note":"First- and second-line metastatic colorectal cancer with fluoropyrimidine-based chemotherapy, only when targeted treatment or immunotherapy is unsuitable.","from":"bevacizumab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Camizestrant approved in EU","note":"ER+/HER2- advanced breast cancer with emergent ESR1 mutation, with a CDK4/6 inhibitor; 20 Jul 2026","from":"camizestrant","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Camizestrant approved in US","note":"HR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026)","from":"camizestrant","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Capivasertib approved in US","note":"PTEN-deficient metastatic prostate cancer with abiraterone","from":"capivasertib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Cemiplimab approved in England (NICE)","note":"Untreated locally advanced non-small-cell lung cancer unsuitable for definitive chemoradiation, or metastatic disease, with PD-L1 in 1 percent or more of tumour cells and no EGFR o...","from":"cemiplimab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Daratumumab approved in US","note":"With teclistamab after ≥1 line (MajesTEC-3); high-risk smouldering myeloma (AQUILA)","from":"daratumumab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Daraxonrasib approved in US","note":"Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or in adults who are not candidates for multiagent systemic therapy.","from":"daraxonrasib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Datopotamab deruxtecan approved in US","note":"First-line unresectable/metastatic TNBC, PD-1/PD-L1 inhibitor ineligible","from":"datopotamab-deruxtecan","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Decitabine + cedazuridine (oral) approved in US","note":"Newly diagnosed AML, unfit for intensive induction, with venetoclax (ASCERTAIN-V)","from":"decitabine-cedazuridine","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Durvalumab approved in US","note":"High-risk NMIBC with BCG","from":"durvalumab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Encorafenib approved in US","note":"First-line BRAF V600E mCRC with cetuximab and chemotherapy","from":"encorafenib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Encorafenib approved in US","note":"Metastatic colorectal cancer with a BRAF V600E mutation. Traditional approval granted 24 February 2026, converting the accelerated approval.","from":"encorafenib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Gedatolisib approved in US","note":"HR+/HER2- advanced breast cancer after CDK4/6 inhibitor (July 2026)","from":"gedatolisib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Iberdomide approved in US","note":"Multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, with subcutaneous daratumumab and dexamethasone (Zenbexus, label effe...","from":"iberdomide","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Imlunestrant approved in EU","note":"ESR1-mutant ER+/HER2- mBC; 9 Jan 2026","from":"imlunestrant","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Isatuximab approved in US","note":"Subcutaneous formulation (Sarclisa Escena)","from":"isatuximab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Lazertinib approved in England (NICE)","note":"Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with amivantamab.","from":"lazertinib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Lurbinectedin approved in EU","note":"Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026","from":"lurbinectedin","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Lutetium-177 vipivotide tetraxetan approved in US","note":"Label expansion (July 2026)","from":"pluvicto","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Nadofaragene firadenovec approved in EU","note":"BCG-unresponsive NMIBC with CIS; 28 May 2026 (conditional). Conditional marketing authorisation","from":"nadofaragene-firadenovec","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Nivolumab approved in England (NICE)","note":"Resectable non-small-cell lung cancer at high risk of recurrence without an EGFR mutation or ALK rearrangement: neoadjuvant with platinum chemotherapy then adjuvant alone.","from":"nivolumab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Nivolumab approved in US","note":"Untreated advanced classical Hodgkin lymphoma with AVD, age ≥12","from":"nivolumab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Nogapendekin alfa inbakicept approved in EU","note":"BCG-unresponsive NMIBC with CIS, with BCG; 16 Feb 2026 (conditional). Conditional marketing authorisation","from":"nogapendekin-alfa","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Optune / Optune Pax (TTFields) approved in US","note":"Locally advanced pancreatic cancer with chemotherapy","from":"optune","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Osimertinib approved in England (NICE)","note":"Unresectable stage III EGFR mutation-positive non-small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy.","from":"osimertinib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Palbociclib approved in US","note":"HR+/HER2+ advanced breast cancer maintenance with anti-HER2 and endocrine therapy","from":"palbociclib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Pembrolizumab approved in US","note":"Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Piflufolastat F-18 / Pylarify TruVu approved in US","note":"Pylarify TruVu formulation","from":"pylarify","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Pivekimab sunirine approved in US","note":"Blastic plasmacytoid dendritic cell neoplasm","from":"pivekimab-sunirine","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Relacorilant approved in US","note":"Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel","from":"relacorilant","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Rusfertide approved in US","note":"Erythrocytosis in adults with polycythaemia vera","from":"rusfertide","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Sacituzumab govitecan approved in EU","note":"First-line unresectable locally advanced or metastatic TNBC in patients who are not candidates for PD-1 or PD-L1 inhibitor therapy (ASCENT-03); listed in the EMA therapeutic indica...","from":"sacituzumab-govitecan","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Sacituzumab govitecan approved in US","note":"First-line metastatic TNBC: monotherapy (PD-1 ineligible) or with pembrolizumab (PD-L1 CPS ≥10)","from":"sacituzumab-govitecan","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Selpercatinib approved in US","note":"Label update (July 2026)","from":"selpercatinib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Serplulimab approved in England (NICE)","note":"Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide. TA1167, published 18 June 2026 (ASTRUM-005); must be funded in England within 90 days of publicati...","from":"serplulimab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Setmelanotide approved in US","note":"Acquired hypothalamic obesity in adults and children aged 4 years and older. Approved 19 March 2026 (Drugs@FDA supplement 9) on the TRANSCEND trial","from":"setmelanotide","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"SimpleScreen CRC approved in US","note":"Colorectal cancer screening in average-risk adults aged 45 and older","from":"simplescreen-crc","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Sonrotoclax approved in US","note":"Relapsed/refractory mantle cell lymphoma after ≥2 lines including a BTK inhibitor (accelerated)","from":"sonrotoclax","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Tarlatamab approved in EU","note":"ES-SCLC after platinum-based chemotherapy; 29 May 2026","from":"tarlatamab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Teclistamab approved in US","note":"Relapsed/refractory myeloma after ≥1 prior therapy","from":"teclistamab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Tovorafenib approved in EU","note":"Relapsed/refractory paediatric low-grade glioma (conditional)","from":"tovorafenib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Trastuzumab deruxtecan approved in US","note":"Early-stage HER2+ breast cancer (neoadjuvant and post-neoadjuvant)","from":"trastuzumab-deruxtecan","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Vepdegestrant approved in US","note":"ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after endocrine therapy","from":"vepdegestrant","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Vusolimogene oderparepvec approved in US","note":"Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)","from":"vusolimogene-oderparepvec","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Zanidatamab approved in UK","note":"HER2-positive (IHC 3+) unresectable locally advanced or metastatic biliary tract cancer after at least one line of systemic treatment; MHRA 19 February 2026, NICE TA1153 published...","from":"zanidatamab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Zenocutuzumab approved in US","note":"NRG1-fusion cholangiocarcinoma","from":"zenocutuzumab","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Zidesamtinib approved in US","note":"ROS1+ NSCLC (July 2026)","from":"zidesamtinib","refs":[]},{"group":"approval","date":"2026","precision":"year","title":"Zongertinib approved in US","note":"First-line HER2-mutant non-squamous NSCLC","from":"zongertinib","refs":[]},{"group":"company","date":"2026","precision":"year","title":"FinalDose founded","note":"San Francisco, CA","from":"finaldose","refs":[]},{"group":"expected","date":"2026","precision":"year","title":"FDA decision on Pluvicto in metastatic hormone-sensitive prostate cancer (PSMAddition)","note":"Expected date. Novartis announced the supplemental filing after the PSMAddition results in 2025. No action date has been disclosed; the year is our estimate.","from":"pluvicto","refs":["novartis","prostate","psma"]},{"group":"funding","date":"2026","precision":"year","title":"Adcendo: Series C","note":"$75m","from":"adcendo","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Allotera Therapeutics (formerly Wugen): Series C","note":"$35m. Additional equity and venture debt closed 8 July 2026, bringing the Series C total to $150 million","from":"allotera-therapeutics","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Arcellx: Acquisition","note":"$7.8bn. $115 per share in cash plus a $5 contingent value right; implied equity value $7.8 billion; completed 28 April 2026","from":"arcellx","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"ClearNote Health: Series D","note":"$52m. Led by founding investor Mattias Westman; cumulative funding stated as over $185 million.","from":"clearnote-health","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Cullgen: Acquisition","note":"$300m. All-stock transaction valued at approximately 300 million US dollars; announced 2 March 2026, closed 4 May 2026","from":"cullgen","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Empyrean Medical Systems: Debt","note":"Hamilton Reserve Bank made an equity investment of undisclosed size and agreed to arrange a credit line of up to USD 20 million to support 2026 product sales","from":"empyrean-medical-systems","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Firefly Bio: Acquisition","note":"$1.0bn. USD 1 billion in cash, announced 8 June 2026; completion announced on the company website 29 July 2026","from":"firefly-bio","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"GT Medical Technologies: Series E","note":"$100m. Oversubscribed; led by new investor Viking Global Investors","from":"gt-medical-technologies","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Kanvas Biosciences: Series A","note":"$48m. Announced via Business Wire, 6 May 2026, as listed on the company news page","from":"kanvas-biosciences","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Kelonia Therapeutics: Acquisition","note":"$3.3bn. Upfront payment of $3.25 billion; up to $7.00 billion in total including clinical, regulatory and commercial milestones; announced 20 April 2026","from":"kelonia-therapeutics","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"MaaT Pharma: Debt","note":"Tranche B of EUR 6 million drawn from a European Investment Bank loan facility in April 2026","from":"maat-pharma","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Monteris Medical: Debt","note":"$35m. Credit facility from Trinity Capital replacing a prior Madryn Asset Management facility","from":"monteris-medical","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Monteris Medical: Series E","note":"$28m. Led by existing investors InnovaHealth Partners and Birchview Capital with new investors OSF Ventures and Colorado University Healthcare Innovation Fund; Madryn Asset Managem...","from":"monteris-medical","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Myricx Bio: Acquisition","note":"$1.1bn. USD 1.1 billion upfront plus up to USD 400 million in milestones; agreement announced 6 July 2026, completed 28 August 2026 per company website","from":"myricx-bio","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Naveris: Acquisition","note":"$160m. CareDx agreed to pay $160 million cash up front plus up to $100 million in revenue milestones (announced 28 April 2026); completion announced July 2026.","from":"naveris","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Neomorph: Series B","note":"$100m. Led by founding investor Deerfield Management; closed April 2026","from":"neomorph","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Nucleus RadioPharma: Series B","note":"$50m. USD 50 million financing from OrbiMed announced 20 April 2026; the company did not name the round, labelled Series B here for schema purposes only","from":"nucleus-radiopharma","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Nykode Therapeutics: Crossover","note":"Public follow-on private placement on Euronext Oslo: NOK 286 million gross, 65 million new shares at NOK 4.40","from":"nykode-therapeutics","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Obsidian Therapeutics: Crossover","note":"$350m. Oversubscribed private placement completed alongside the reverse merger with Galera Therapeutics; shares began trading on Nasdaq as OBX on 4 August 2026","from":"obsidian-therapeutics","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"OSE Immunotherapeutics: Crossover","note":"Flexible bridge equity financing (warrants) with IRIS Capital Investment: up to 4 million new shares, gross proceeds up to about EUR 19.3 million over 24 months at the then share p...","from":"ose-immunotherapeutics","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Perimeter Medical Imaging AI: Crossover","note":"Listed issuer financing exemption (LIFE) unit offering: approximately CAD 6.84 million closed 5 May 2026 with a final tranche to bring the total to CAD 7.52 million; led by Paradig...","from":"perimeter-medical-imaging-ai","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Perimeter Medical Imaging AI: Debt","note":"CAD 6.04 million of 3.59 percent convertible debentures maturing April 2029, including CAD 2.76 million from CEO Adrian Mendes","from":"perimeter-medical-imaging-ai","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Quantum Surgical: Grant","note":"PreciseOnco consortium (with Philips, IGEA, EIBIR and CIRSE) awarded EUR 14.9 million public funding from the EU Innovative Health Initiative plus EUR 9 million in-kind, EUR 23.9 m...","from":"quantum-surgical","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Ratio Therapeutics: Series C","note":"$70m. Brings total capital raised to over USD 240 million","from":"ratio-therapeutics","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Reimagine Care: Acquisition","note":"Acquired by Cureety (Paris) in September 2026; financial terms not disclosed","from":"reimagine-care","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Repare Therapeutics: Acquisition","note":"All shares acquired by non-profit XenoTherapeutics for about 2.20 US dollars per share in cash plus a contingent value right; total deal value not stated","from":"repare-therapeutics","refs":[]},{"group":"funding","date":"2026","precision":"year","title":"Thyme Care: Series E","note":"$125m. USD 125 million plus, led by Morgan Health; valuation stated as more than USD 2 billion","from":"thyme-care","refs":[]},{"group":"history","date":"2026","precision":"year","title":"A CA 19-9 cut-off for the Lewis-negative tenth","note":"Pancreatic ductal adenocarcinoma. FUT3-null patients, about 10%, have median CA 19-9 of 2.4 U/mL and the same poor survival as patients above 200; a value of 7 or below identifies...","from":"pancreatic","refs":["paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026","paper-worthington-precede-early-detection-biomarkers-ijc-2026","paper-daraxonrasib-pancreatic-n-engl-j-med-2026"]},{"group":"history","date":"2026","precision":"year","title":"Acalabrutinib frontline label expanded","note":"Chronic lymphocytic leukaemia","from":"cll","refs":[]},{"group":"history","date":"2026","precision":"year","title":"ANBL1531 MIBG randomisation maturing; ALK arm reports","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":["anbl1531"]},{"group":"history","date":"2026","precision":"year","title":"ASCO 2026: NeoVax personalised vaccine immune responses; multi-target CAR-T; tovorafenib EU approval","note":"Glioma & glioblastoma","from":"glioblastoma","refs":["tovorafenib","glioma-car-t","idea-neoadjuvant-io-glioblastoma"]},{"group":"history","date":"2026","precision":"year","title":"AZUR-1 confirms non-operative management with dostarlimab in mismatch-repair deficient rectal cancer","note":"Rectal cancer","from":"rectal-cancer","refs":["azur-1"]},{"group":"history","date":"2026","precision":"year","title":"Bispecific ADC succeeds; first-line ADC approvals","note":"Triple-negative breast cancer (TNBC). Iza-bren phase 3 positive (Feb 2026); FDA approves Dato-DXd and sacituzumab govitecan first line (Q2 2026).","from":"tnbc","refs":["bl-b01d1-307","datopotamab-deruxtecan","sacituzumab-govitecan"]},{"group":"history","date":"2026","precision":"year","title":"BREAKWATER FOLFIRI cohort and full approval; AZUR-1 priority review; T-DXd and RAS(ON) inhibitors advance","note":"Colorectal cancer","from":"colorectal","refs":["breakwater","azur-1","daraxonrasib"]},{"group":"history","date":"2026","precision":"year","title":"CAPBIL: first UK nationwide gallbladder cancer cohorts","note":"Gallbladder cancer. 285 incidental cancers and 516 operated patients across 24 centres, 2014 to 2022; 67.7 percent of incidental cancers had liver resection.","from":"gallbladder","refs":["paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026","paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026"]},{"group":"history","date":"2026","precision":"year","title":"Capivasertib for PTEN-deficient and 177Lu-PSMA-617 for PSMA-positive disease approved","note":"Metastatic hormone-sensitive prostate cancer","from":"prostate-mhspc","refs":["capitello-281","psmaddition","capivasertib","pluvicto"]},{"group":"history","date":"2026","precision":"year","title":"DAREON-NEC-1 phase 3 of obrixtamig with carboplatin-etoposide opens in DLL3-positive extrapulmonary carcinoma","note":"Extrapulmonary neuroendocrine carcinoma","from":"extrapulmonary-nec","refs":["nct07544654"]},{"group":"history","date":"2026","precision":"year","title":"DREAM3R stopped early; PRMT5 inhibitors and mesothelin cell therapies advance","note":"Mesothelioma","from":"mesothelioma","refs":["dream3r","idea-mtap-prmt5-mesothelioma","idea-mesothelin-car-t-regional"]},{"group":"history","date":"2026","precision":"year","title":"EMERALD-3 positive for PFS; LEAP-012 final OS HR 0.98; IMbrave050 update negative; third camrelizumab-rivoceranib CRL (23 July)","note":"Hepatocellular carcinoma","from":"hcc","refs":["emerald-3","leap-012","imbrave050","cares-310"]},{"group":"history","date":"2026","precision":"year","title":"EMERALD-3: durvalumab-tremelimumab plus TACE reported positive","note":"Intermediate hepatocellular carcinoma (BCLC B)","from":"hcc-intermediate","refs":["emerald-3"]},{"group":"history","date":"2026","precision":"year","title":"FDA accepts 177Lu-edotreotide NDA (PDUFA 28 August); ACTION-1 dosimetry published; pancreatic subgroup of COMPETE at ENETS","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":["itm-11","action-1"]},{"group":"history","date":"2026","precision":"year","title":"First all-oral AML regimen","note":"Acute myeloid leukaemia. Decitabine-cedazuridine + venetoclax approved 13 May 2026 (ASCERTAIN-V, CR 41.6%).","from":"aml","refs":["decitabine-cedazuridine","ascertain-v"]},{"group":"history","date":"2026","precision":"year","title":"First PROTAC (vepdegestrant), gedatolisib, and the first ctDNA-triggered switch (camizestrant) approved; persevERA fails upfront","note":"HR-positive / HER2-negative breast cancer","from":"breast-hr-positive","refs":["vepdegestrant","veritac-2","gedatolisib","camizestrant"]},{"group":"history","date":"2026","precision":"year","title":"First US all-oral fixed-duration regimen; sonrotoclax US approval (MCL); BTK degrader phase 3","note":"Chronic lymphocytic leukaemia. Acalabrutinib-venetoclax approved 19 February; sonrotoclax accelerated approval 13 May; CaDAnCe-304 and CELESTIAL-TNCLL enrolling.","from":"cll","refs":["acalabrutinib","amplify","sonrotoclax","bgb-16673"]},{"group":"history","date":"2026","precision":"year","title":"First-line antibody-drug conjugate approvals; izalontamab brengitecan phase 3 positive","note":"Metastatic triple-negative breast cancer","from":"tnbc-metastatic","refs":["datopotamab-deruxtecan","sacituzumab-govitecan","bl-b01d1-307"]},{"group":"history","date":"2026","precision":"year","title":"Five years of the NHS England programme reported","note":"Lung cancer (all types). Over two million people invited and 7,193 lung cancers diagnosed to March 2025, 63.1 percent at stage 1 and 12.6 percent at stage 2, with the early-stage s...","from":"lung-cancer","refs":["nhs-targeted-lung-health-check"]},{"group":"history","date":"2026","precision":"year","title":"frontMIND published in Lancet; EPCORE DLBCL-1 misses OS; frontline bispecific data (EPCORE DLBCL-2) at EHA","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["frontmind","epcore-dlbcl-1","epcore-dlbcl-2"]},{"group":"history","date":"2026","precision":"year","title":"Full approval of the first-line triplet","note":"BRAF V600E-mutant colorectal cancer","from":"braf-v600e-colorectal","refs":["encorafenib","breakwater"]},{"group":"history","date":"2026","precision":"year","title":"HER2-ultralow share of TNBC measured","note":"Triple-negative breast cancer (TNBC). Boissiere-Michot reclassifies 367 untreated TNBCs as 38% null, 38% ultralow and 24% low, none prognostic; ultralow stays unlabelled in TNBC.","from":"tnbc","refs":["paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026","her2-ultralow"]},{"group":"history","date":"2026","precision":"year","title":"HERIZON-GEA-01: zanidatamab beats trastuzumab; CLARITY-Gastric 01: first CLDN18.2 ADC with OS benefit","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["herizon-gea-01","clarity-gastric01"]},{"group":"history","date":"2026","precision":"year","title":"IMvigor011 ctDNA-guided atezolizumab and POTOMAC durvalumab + BCG approved; cretostimogene BLA under way","note":"Bladder & urothelial cancer","from":"urothelial","refs":["imvigor011","potomac","cretostimogene"]},{"group":"history","date":"2026","precision":"year","title":"IMvigor011: ctDNA-guided atezolizumab approved","note":"Bladder & urothelial cancer","from":"urothelial","refs":["imvigor011"]},{"group":"history","date":"2026","precision":"year","title":"Incidence falls in the old and rises in the young","note":"Colorectal cancer. The American Cancer Society reports colorectal cancer incidence rising 3 percent a year in adults aged 20 to 49 and 0.4 percent a year at 50 to 64, while falling...","from":"colorectal","refs":["early-onset-colorectal"]},{"group":"history","date":"2026","precision":"year","title":"INTerpath-001 positive in resected stage IIB to IV melanoma","note":"Stage IIB and IIC melanoma","from":"stage-ii-melanoma","refs":["interpath-001","intismeran-autogene"]},{"group":"history","date":"2026","precision":"year","title":"INTerpath-001: first positive phase 3 personalised vaccine trial","note":"Stage III melanoma (after surgery)","from":"stage-iii-melanoma","refs":["interpath-001","intismeran-autogene"]},{"group":"history","date":"2026","precision":"year","title":"Intismeran autogene phase 3 positive; RP1 approved with nivolumab; fianlimab-cemiplimab phase 3 misses; brenetafusp phase 3 enrolling","note":"Melanoma","from":"melanoma","refs":["interpath-001","intismeran-autogene","vusolimogene-oderparepvec","fianlimab-phase3-melanoma"]},{"group":"history","date":"2026","precision":"year","title":"Intismeran phase 3 positive; RP1 approved","note":"Melanoma","from":"melanoma","refs":["interpath-001","vusolimogene-oderparepvec"]},{"group":"history","date":"2026","precision":"year","title":"Iza-bren phase 3 positive","note":"Oesophageal cancer","from":"esophageal","refs":["bl-b01d1-307"]},{"group":"history","date":"2026","precision":"year","title":"LITESPARK-022 positive and approved (adjuvant belzutifan + pembrolizumab); LITESPARK-012 first-line triplet falls short","note":"Renal cell carcinoma","from":"rcc","refs":["litespark-022","litespark-012"]},{"group":"history","date":"2026","precision":"year","title":"METRO PLUS: metronomic tablets with paclitaxel-carboplatin double survival","note":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","from":"buccal-mucosa-cancer","refs":["metro-plus-varanasi"]},{"group":"history","date":"2026","precision":"year","title":"Nivolumab-AVD approved by FDA (20 March) for ages 12+; HD21 5-year data confirm BrECADD","note":"Hodgkin lymphoma","from":"hodgkin-lymphoma","refs":["swog-s1826","nivolumab","hd21"]},{"group":"history","date":"2026","precision":"year","title":"Nivolumab-AVD approved first line","note":"Hodgkin lymphoma","from":"hodgkin-lymphoma","refs":["nivolumab"]},{"group":"history","date":"2026","precision":"year","title":"PANKU-Esophagus01: iza-bren improves OS in second-line ESCC; HERIZON-GEA-01 for HER2+ GEJ; CheckMate 648 five-year data","note":"Oesophageal cancer","from":"esophageal","refs":["panku-esophagus01","herizon-gea-01","checkmate-648"]},{"group":"history","date":"2026","precision":"year","title":"Phase 3 readouts pending for I-DXd and tarlatamab maintenance","note":"Small-cell lung cancer","from":"sclc","refs":["ideate-lung02","dellphi-305"]},{"group":"history","date":"2026","precision":"year","title":"Pivekimab sunirine approved","note":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN). CD123 ADC (CADENZA), FDA May 2026.","from":"bpdcn","refs":["pivekimab-sunirine"]},{"group":"history","date":"2026","precision":"year","title":"Pluvicto approved in metastatic hormone-sensitive disease (31 July); capivasertib + abiraterone approved for PTEN-deficient disease","note":"Prostate cancer","from":"prostate","refs":["psmaddition","pluvicto","capitello-281","capivasertib"]},{"group":"history","date":"2026","precision":"year","title":"RASolute 302: daraxonrasib lengthens survival after first-line chemotherapy, the first RAS inhibitor to do so","note":"Metastatic pancreatic ductal adenocarcinoma","from":"metastatic-pdac","refs":["rasolute-302","daraxonrasib","revolution-medicines"]},{"group":"history","date":"2026","precision":"year","title":"RASolute 302: daraxonrasib OS 13.2 vs 6.7 months (HR 0.40)","note":"Pancreatic ductal adenocarcinoma. ASCO plenary and NEJM; FDA approval of daraxonrasib on 26 August 2026; Optune Pax approved; zoldonrasib combinations reported; AMPLIFY-7P vaccine...","from":"pancreatic","refs":["rasolute-302","optune","zoldonrasib","amplify-7p"]},{"group":"history","date":"2026","precision":"year","title":"RASolute 302: daraxonrasib, active against all RAS variants, lengthens survival after chemotherapy","note":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","from":"kras-g12c-pdac","refs":["rasolute-302","daraxonrasib"]},{"group":"history","date":"2026","precision":"year","title":"Relacorilant and pembrolizumab approved for platinum-resistant ovarian cancer","note":"Platinum-resistant ovarian cancer","from":"platinum-resistant-ovarian-cancer","refs":["relacorilant","pembrolizumab"]},{"group":"history","date":"2026","precision":"year","title":"Relacorilant and pembrolizumab approved in platinum-resistant disease","note":"Ovarian cancer","from":"ovarian","refs":["relacorilant"]},{"group":"history","date":"2026","precision":"year","title":"Relacorilant and pembrolizumab approved in platinum-resistant disease","note":"Ovarian cancer. First immunotherapy approval in ovarian cancer (February 2026).","from":"ovarian","refs":["relacorilant","pembrolizumab","keynote-b96"]},{"group":"history","date":"2026","precision":"year","title":"RP1 with nivolumab approved for PD-1-refractory melanoma","note":"Advanced melanoma (unresectable stage III and stage IV)","from":"advanced-melanoma","refs":["vusolimogene-oderparepvec"]},{"group":"history","date":"2026","precision":"year","title":"Rusfertide approved","note":"Polycythaemia vera (PV). FDA approval for phlebotomy-dependent polycythaemia vera.","from":"polycythaemia-vera","refs":["rusfertide"]},{"group":"history","date":"2026","precision":"year","title":"Rusfertide approved for PV","note":"Myeloproliferative neoplasms (PV, ET, myelofibrosis). VERIFY: hepcidin mimetic controls erythrocytosis without phlebotomy; FDA approval August 2026.","from":"myeloproliferative-neoplasms","refs":["rusfertide"]},{"group":"history","date":"2026","precision":"year","title":"Selinexor maintenance fails (XPORT-EC-042)","note":"Endometrial cancer. Post-hoc TP53-wild-type subgroup hypothesis not confirmed.","from":"endometrial","refs":["xport-ec-042","selinexor"]},{"group":"history","date":"2026","precision":"year","title":"Selpercatinib label update (July 2026)","note":"Thyroid cancer","from":"thyroid","refs":["selpercatinib"]},{"group":"history","date":"2026","precision":"year","title":"Sonrotoclax approved for relapsed MCL","note":"Mantle cell lymphoma","from":"mantle-cell-lymphoma","refs":["sonrotoclax"]},{"group":"history","date":"2026","precision":"year","title":"Subcutaneous blinatumomab and Interfant-21 progress","note":"Acute lymphoblastic leukaemia. Subcutaneous blinatumomab trials (including the first in mixed-phenotype leukaemia) aim to replace continuous infusion; infant trials integrate blina...","from":"all-leukemia","refs":["blinatumomab","interfant-06"]},{"group":"history","date":"2026","precision":"year","title":"T-DXd approved neoadjuvant and post-neoadjuvant; palbociclib maintenance for HR+/HER2+ (PATINA)","note":"HER2-positive breast cancer","from":"breast-her2-positive","refs":["destiny-breast11","destiny-breast05","palbociclib"]},{"group":"history","date":"2026","precision":"year","title":"Tazemetostat withdrawn worldwide","note":"Follicular lymphoma. Secondary haematologic malignancies; EZH2 leaves the FL armamentarium.","from":"follicular-lymphoma","refs":["tazemetostat"]},{"group":"history","date":"2026","precision":"year","title":"Tazemetostat withdrawn worldwide","note":"Epithelioid sarcoma. Ipsen withdraws tazemetostat in all indications on 9 March 2026 after the SYMPHONY-1 data monitoring committee flagged secondary haematologic malignancies (18/...","from":"epithelioid-sarcoma","refs":["tazemetostat"]},{"group":"history","date":"2026","precision":"year","title":"Tazemetostat withdrawn worldwide (9 March); afami-cel full approval and age ≥12 (June); INSIGHT positive","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["afamitresgene-autoleucel","insight-gist","ezh2"]},{"group":"history","date":"2026","precision":"year","title":"Teclistamab + daratumumab approved after ≥1 line (MajesTEC-3); isatuximab subcutaneous; anito-cel BLA accepted (PDUFA December)","note":"Multiple myeloma","from":"multiple-myeloma","refs":["majestec-3","isatuximab","anitocabtagene-autoleucel"]},{"group":"history","date":"2026","precision":"year","title":"Teclistamab after ≥1 line; isatuximab SC","note":"Multiple myeloma","from":"multiple-myeloma","refs":[]},{"group":"history","date":"2026","precision":"year","title":"TNM 9 takes effect, and leaves breast staging alone","note":"Breast cancer (all types). Published 3 July 2025 and recommended from 1 January 2026. For breast the classification is unchanged; the yp classification is clarified, basing ypT on...","from":"breast-cancer","refs":["tnm-breast-cancer-editions","rcb"]},{"group":"history","date":"2026","precision":"year","title":"TROPION-Breast02 and OlympiA six-year update published; CAPItello-290 negative","note":"Triple-negative breast cancer (TNBC). Datopotamab deruxtecan first line: overall survival 23.7 vs 18.7 months.","from":"tnbc","refs":["paper-tropion-breast02-ann-oncol-2026","paper-olympia-6-year-update-ann-oncol-2026","paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026","tropion-breast02"]},{"group":"history","date":"2026","precision":"year","title":"Tumour treating fields device approved for locally advanced pancreatic cancer","note":"Locally advanced unresectable pancreatic ductal adenocarcinoma","from":"locally-advanced-pdac","refs":["optune","novocure"]},{"group":"history","date":"2026","precision":"year","title":"Vepdegestrant, the first PROTAC, approved","note":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","from":"hr-positive-metastatic-post-cdk46","refs":["vepdegestrant"]},{"group":"history","date":"2026","precision":"year","title":"WHO classification of breast tumours, 6th edition","note":"Breast cancer (all types). Published April 2026. Reserves 'variant' for molecular alterations and separates subtype from pattern, updates the HER2 reporting categories so that no m...","from":"breast-cancer","refs":["who-breast-classification"]},{"group":"history","date":"2026","precision":"year","title":"World Health Assembly calls for accountable elimination systems; sac-TMT and TIL trials in recurrent disease","note":"Cervical cancer","from":"cervical","refs":["sacituzumab-tirumotecan","lifileucel"]},{"group":"history","date":"2026","precision":"year","title":"XPORT-EC-042: maintenance selinexor fails in TP53-wild-type disease","note":"Endometrial cancer with no specific molecular profile","from":"endometrial-nsmp","refs":["xport-ec-042","selinexor"]},{"group":"history","date":"2026","precision":"year","title":"XPORT-EC-042: maintenance selinexor fails in TP53-wild-type disease","note":"Advanced or recurrent endometrial cancer","from":"advanced-recurrent-endometrial-cancer","refs":["xport-ec-042"]},{"group":"history","date":"2026","precision":"year","title":"Zenocutuzumab approved for NRG1-fusion cholangiocarcinoma; HERIZON-BTC-302 enrolling","note":"Biliary tract cancer (cholangiocarcinoma)","from":"cholangiocarcinoma","refs":["zenocutuzumab","herizon-btc-302"]},{"group":"history","date":"2026","precision":"year","title":"Zongertinib first line; zidesamtinib (ROS1) approved; divarasib beats first-generation KRAS inhibitors; neladalkib and ivonescimab under FDA review","note":"Non-small-cell lung cancer","from":"nsclc","refs":["zongertinib","zidesamtinib","krascendo-1","neladalkib"]},{"group":"paper","date":"2026","precision":"year","title":"[ 177 Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, c...","note":"Tagawa ST, Sartor O, Piulats JM, et al. The Lancet.","from":"paper-psmaddition-lancet-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors","note":"Mahadevan D, Parekh J, Beck JT, et al. Investigational new drugs.","from":"paper-nct05933265-invest-new-drugs-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"A new CA19-9 cutoff value identifies Lewis antigen status and refines prognostic stratification in PDAC","note":"Yeh CM, Yu CC, Lee AF, et al. Clinical Cancer Research.","from":"paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advance...","note":"Robert M, Kotecki N, Gomez-Roca C, et al. European Journal of Cancer.","from":"paper-nct05751798-eur-j-cancer-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results f...","note":"Zhou H, Zhou Q, Guo Q, et al. Lung cancer.","from":"paper-nct05195632-lung-cancer-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","note":"Wu YL, Majem M, John T, et al. Journal of Thoracic Oncology.","from":"paper-adaura-8-year-os-jto-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-con...","note":"DeWeese TL, Manzanera A, Sylvester J, et al. The Lancet Oncology.","from":"paper-nct01436968-lancet-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study","note":"Oberstein PE, Hecht JR, Raghav K, et al. Journal of Clinical Oncology.","from":"paper-nct05379595-j-clin-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"An anti-PMEL antibody-drug conjugate with a G q/1 1 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial","note":"Carlino MS, Kapiteijn E, Piperno-Neumann S, et al. Nature Medicine.","from":"paper-nct05415072-nat-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study","note":"Yang JJ, Mu Y, Wang ZH, et al. Journal of Thoracic Oncology.","from":"paper-nct06015503-j-thorac-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients","note":"Armstrong AJ, Petrylak DP, Shore ND, et al. European Urology.","from":"paper-arches-eur-urol-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer","note":"Sinicrope FA, Ou FS, Arnold D, et al. New England Journal of Medicine.","from":"paper-atomic-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial","note":"Zhang L, Zhang X, Wu L, et al. The Lancet Oncology.","from":"paper-nct04687241-lancet-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, pha...","note":"Li Z, Hu J, Chen J, et al. The Lancet Oncology.","from":"paper-nct04923906-lancet-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, con...","note":"Motzer RJ, McDermott R, Park SH, et al. The Lancet.","from":"paper-litespark-011-motzer-lancet-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology","note":"Gradishar WJ, Moran MS, Abraham J, et al. Journal of the National Comprehensive Cancer Network.","from":"paper-nccn-breast-cancer-v4-2026-jnccn-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"c-TRAK TN analysis: tissue-free versus tumour-informed ctDNA assays for residual disease in early triple-negative breast cancer","note":"Cunningham N, Cutts RJ, Swift C, et al. JAMA Oncology.","from":"paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Cancer therapy using antiparasitic medications guided by acupuncture meridian assessment: a case series of six patients","note":"Guilford FT, Yu S. Integrative Medicine (Encinitas).","from":"paper-guilford-antiparasitic-acupuncture-meridian-case-series-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","note":"Fizazi K, Clarke NW, De Santis M, et al. Annals of Oncology.","from":"paper-capitello-281-ann-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 t...","note":"Schmid P, McArthur HL, Cortés J, et al. Annals of Oncology.","from":"paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target","note":"Tamrakar VK, Sharma K, Singh P, et al. Cancer.","from":"paper-tamrakar-cancer","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Clinical Utility of an Ex Vivo Functional Test in Personalized Cancer Treatment","note":"Bar V, Zundelevich A, Gavert N, et al. Journal of personalized medicine.","from":"paper-bar-j-pers-med","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer","note":"Wolpin BM, Park W, Garrido-Laguna I, et al. New England Journal of Medicine.","from":"paper-nct05379985-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","note":"O'Reilly EM, Wainberg ZA, Hendifar AE, et al. New England Journal of Medicine.","from":"paper-daraxonrasib-pancreatic-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma","note":"Zacharia GS, Pandey U, Thartori O, et al. Cureus.","from":"paper-daraxonrasib-pancreatic-cureus-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial","note":"Saad F, Shore N, Vjaters E, et al. European Urology.","from":"paper-aranote-eur-urol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast...","note":"Schmid P, Wang HC, Lynce F, et al. Annals of Oncology.","from":"paper-nct03742102-ann-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III...","note":"Dent R, Shao Z, Schmid P, et al. Annals of Oncology.","from":"paper-tropion-breast02-ann-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial","note":"Huang J, Chen G, Wang Z, et al. Journal of Thoracic Oncology.","from":"paper-nct05955391-j-thorac-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: result...","note":"Wu J, Li X, Gu C, et al. Signal transduction and targeted therapy.","from":"paper-nct03851640-signal-transduct-target-ther-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations","note":"Suter RK, Jermakowicz AM, Veeramachaneni R, et al. Nature Communications.","from":"paper-santosh-kesari-nat-commun-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: a case report","note":"Powderly GE, Hassevoort K, Loy M, Balonier J, Sievers C. Cureus.","from":"paper-powderly-fenbendazole-ivermectin-liver-injury-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Labe...","note":"Li JJ, Zhang WJ, Zeng XH, et al. Journal of Clinical Oncology.","from":"paper-nct06198751-j-clin-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer","note":"Tang W, Lv Y, Xie H, et al. Cancer letters.","from":"paper-nct05300269-cancer-lett-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02","note":"Oh DY, Lugowska I, Stroyakovskiy D, et al. ESMO Open.","from":"paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial","note":"Mahalingam D, Shroff RT, Carneiro BA, et al. Nature Medicine.","from":"paper-mahalingam-nat-med","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial","note":"Wen PY, Berry DA, Buxton MB, et al. Journal of Clinical Oncology.","from":"paper-wen-j-clin-oncol","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-null to HER2-low, including HER2-ultralow status","note":"Boissiere-Michot F, Gudin-De-Vallerin A, Thezenas S, et al. Virchows Archiv.","from":"paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies","note":"Xin X, Miao R. Cancers.","from":"paper-fgfr2-cholangiocarcinoma-cancers-basel-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, random...","note":"Liu Y, Zhang Y, Lin R, et al. Signal transduction and targeted therapy.","from":"paper-nct04854668-signal-transduct-target-ther-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial","note":"Shao X, Tian C, Chen Z, et al. Nature Medicine.","from":"paper-nct05227664-nat-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","note":"Reck M, Patel JD, Gray JE, et al. Journal of Thoracic Oncology.","from":"paper-nct05186974-j-thorac-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations","note":"Zhou C, Greillier L, Liu G, et al. New England Journal of Medicine.","from":"paper-nct05668988-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study","note":"Wakelee H, Spicer JD, Gao S, et al. Annals of Oncology.","from":"paper-keynote-671-ann-oncol-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer","note":"Planchard D, Jänne PA, Yang JC, et al. Lung Cancer.","from":"paper-flaura2-long-term-safety-lung-cancer-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis","note":"Gárate-Calderón V, Kumar R, Marcelain K, et al. EBioMedicine.","from":"paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Glecirasib plus sitneprotafib in patients with KRAS G12C -mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial","note":"Zhong J, Zhao J, Duan J, et al. The Lancet. Respiratory medicine.","from":"paper-nct05288205-lancet-respir-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial","note":"Cho BC, Balaraman R, Chen HJ, et al. Nature Medicine.","from":"paper-nct05671510-nat-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"HER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: concordance between immunohistochemistry and chromogenic in situ hybridization in 140...","note":"Angerilli V, Gasparello J, Niero M, et al. Human Pathology.","from":"paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastati...","note":"Dieras V, Curigliano G, Martin M, et al. Journal of Clinical Oncology.","from":"paper-her2climb-05-j-clin-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results","note":"Braun DA, Noel MS, Moy RH, et al. Cell reports. Medicine.","from":"paper-nct05128487-cell-rep-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Implementation and audit of mainstream genetic testing within a high-volume UK breast unit for pathogenic variations associated with breast cancer using the R20...","note":"Conroy S, Keane E, Rehman B, et al. The Breast Journal.","from":"paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity...","note":"Kapoor A, Gupta A, Sansar B, et al. JCO global oncology.","from":"paper-kapoor-jco-glob-oncol","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study","note":"Khattak A, Carlino MS, Meniawy T, et al. Journal of Clinical Oncology.","from":"paper-nct03897881-j-clin-oncol-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Ivermectin toxicity in humans and animals: clinical spectrum, mechanisms, and management","note":"Yilmaz S, Göktaş B, Ateş İ, Çelik M. Journal of Applied Toxicology.","from":"paper-yilmaz-ivermectin-toxicity-j-appl-toxicol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Ivermectin-benzimidazole prescribing following celebrity endorsement","note":"Rockwell MS, Kahn KL, Fendrick AM, Vangala S, Mafi JN. JAMA Network Open.","from":"paper-rockwell-ivermectin-benzimidazole-prescribing-jama-netw-open-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EG...","note":"Le X, Passaro A, Zhao Y, et al. The Lancet Oncology.","from":"paper-nct06396065-lancet-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analys...","note":"Lu S, Liu B, Luo Y, et al. The Lancet.","from":"paper-nct05840016-lancet-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","note":"Barlesi F, Yao W, Duruisseaux M, et al. Future Oncology.","from":"paper-krystal-12-plain-language-summary-future-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma","note":"Ballman KV. Journal of Clinical Oncology.","from":"paper-ballman-j-clin-oncol","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report","note":"Saperstein Y, Bou Sanayeh E, Boazak P, Itani H, Moussa E, Gut T. Postgraduate Medicine.","from":"paper-saperstein-ivermectin-neurotoxicity-breast-cancer-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial","note":"Kaminski MF, Kalager M, Løberg M, et al. The Lancet.","from":"paper-nordicc-lancet-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study","note":"Li W, Zhang Y, Fan H, et al. Journal of Clinical Oncology.","from":"paper-nct04395677-j-clin-oncol-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial","note":"Sushentsev N, Warren AY, Colling R, et al. BJU international.","from":"paper-protect-bju-int-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Management of incidental gallbladder cancer in the nationwide CAPBIL study","note":"McClements J, Lee WT, Koh A, et al. British Journal of Surgery.","from":"paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"MATRix/IELSG43: high-dose chemotherapy and autologous stem cell transplant versus non-myeloablative consolidation in primary CNS lymphoma","note":"Illerhaus G, Ferreri AJM, Wendler J, et al. The Lancet.","from":"paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Metastatic melanoma with initial ctDNA decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression?","note":"Cheng R, Araujo DV. Frontiers in Oncology.","from":"paper-cheng-melanoma-ctdna-antiparasitic-front-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer","note":"Cowzer D, Walch H, Atri P, et al. Clinical Cancer Research.","from":"paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"NCI9673 part B: randomised phase 2 study of nivolumab with or without ipilimumab in refractory metastatic anal cancer","note":"Morris VK, Ciombor KK, Xiao L, et al. Journal of Clinical Oncology.","from":"paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial","note":"Li J, Liu T, Yu KD, et al. JAMA Oncology.","from":"paper-nct06747338-jama-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III...","note":"Hauschild A, Hassel JC, Ziemer M, et al. Journal of Clinical Oncology.","from":"paper-nct02938299-j-clin-oncol-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast1...","note":"Harbeck N, Modi S, Pusztai L, et al. Annals of Oncology.","from":"paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"New HPV Vaccines on the Market and Future Trends: A State-of-the-Art Review","note":"Akgör U, Temiz BE, Cengiz M, et al. Vaccines.","from":"paper-akgor-vaccines-basel","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Overall survival with abemaciclib in early breast cancer","note":"Johnston S, Martin M, O'Shaughnessy J, et al. Annals of Oncology.","from":"paper-monarche-ann-oncol-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer","note":"Metzger O, Mandrekar S, Goel S, et al. New England Journal of Medicine.","from":"paper-patina-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","note":"Murciano-Goroff YR, Hollebecque A, Heist RS, et al. Nature Communications.","from":"paper-nct04956640-nat-commun-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium","note":"Worthington C, Raitses-Gurevich M, Innamorati G, et al. International Journal of Cancer.","from":"paper-worthington-precede-early-detection-biomarkers-ijc-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer","note":"Agarwal N, Matsubara N, Azad AA, et al. New England Journal of Medicine.","from":"paper-nct04821622-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study","note":"Casarini IA, Kowalski DM, Caglevic C, et al. JCO Oncology Practice.","from":"paper-nct06099782-jco-oncol-pract-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","note":"Neal RD, Dolly S, Johnson P, et al. Nature Medicine.","from":"paper-nhs-galleri-performance-nat-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Perioperative Apalutamide in High-Risk Localized Prostate Cancer","note":"Taplin ME, Gleave M, Shore ND, et al. New England Journal of Medicine.","from":"paper-nct03767244-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315...","note":"Wang C, Wang W, Liu H, et al. Annals of Oncology.","from":"paper-nct04379635-ann-oncol-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors","note":"Dumbrava EE, Shapiro GI, Parikh AR, et al. New England Journal of Medicine.","from":"paper-nct04585750-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma","note":"Lee JB, Baek S, Kim DK, et al. Journal for ImmunoTherapy of Cancer.","from":"paper-nct05877430-j-immunother-cancer-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Pugh 2026: should a journal publish a scientist's experiment on herself?","note":"Pugh J, Wilkinson D, Savulescu J. Journal of Medical Ethics.","from":"paper-pugh-self-experimentation-publication-jme-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer","note":"Malla M, Esmail A, Tin A, et al. ESMO Gastrointestinal Oncology.","from":"paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern)","note":"Hulscher N, Victory K, Thorp JA, et al. Anticancer Research.","from":"paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Research progress of GPC3 and gastric cancer: Clinicopathologic characteristics and application prospects","note":"Ma H, Li Z, Shu P, et al. Pathology, research and practice.","from":"paper-gpc3-gastric-pathol-res-pract-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial","note":"Esserman LJ, Fiscalini AS, Naeim A, et al. JAMA.","from":"paper-wisdom-trial-jama-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer","note":"Tolaney SM, de Azambuja E, Kalinsky K, et al. New England Journal of Medicine.","from":"paper-ascent-04-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR -Mutated Advanced NSCLC","note":"Fang W, Wu L, Meng X, et al. New England Journal of Medicine.","from":"paper-nct05870319-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a r...","note":"Xiong A, Yao W, Zheng W, et al. The Lancet.","from":"paper-nct06448312-lancet-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study","note":"Tutt A, Nowecki Z, Szoszkiewicz R, et al. Clinical Cancer Research.","from":"paper-nct03330847-clin-cancer-res-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer","note":"Wu YL, Hochmair M, Yang Y, et al. New England Journal of Medicine.","from":"paper-nct04819100-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Setmelanotide for the treatment of acquired hypothalamic obesity (TRANSCEND)","note":"Miller JL, van Santen HM, Phillips SA, et al. New England Journal of Medicine.","from":"paper-transcend-miller-nejm-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung...","note":"Peters S, Herbst R, Horinouchi H, et al. Journal of Clinical Oncology.","from":"paper-peters-j-clin-oncol","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Pati...","note":"Lu S, Fang J, Yu Y, et al. Journal of Thoracic Oncology.","from":"paper-nct04665856-j-thorac-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Surgical outcomes in gallbladder cancer: evidence from the UK nationwide CAPBIL study","note":"McClements J, Lee WT, Lucocq J, et al. HPB.","from":"paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the...","note":"Garber JE, Cameron D, Campbell C, et al. Annals of Oncology.","from":"paper-olympia-6-year-update-ann-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial","note":"Wu F, Zhang W, Zhao Y, et al. Journal of Thoracic Oncology.","from":"paper-nct05168566-j-thorac-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy","note":"Zhao Y, Liu H, Meng X, et al. New England Journal of Medicine.","from":"paper-nct06612151-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis...","note":"Girard N, Goldman J, Lu S, et al. JTO clinical and research reports.","from":"paper-luminosity-jto-clin-res-rep-2026-update","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"The impact of expanded access to germline high penetrance genetic testing for women with a new diagnosis of invasive breast cancer or high-grade DCIS","note":"Hudson-Phillips SP, Nanda A, Attia M, et al. Clinical Breast Cancer.","from":"paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial","note":"Browne IM, Pascual J, Cutts RJ, et al. Clinical Cancer Research.","from":"paper-browne-clin-cancer-res","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Timing of revision surgery for incidental gallbladder cancer: a systematic review and individual patient data meta-analysis","note":"Selvakumar B, Patkar S, Nekarakanti PK, et al. HPB.","from":"paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomi...","note":"Zhang J, Ouyang Q, Zhang Q, et al. Journal of Clinical Oncology.","from":"paper-nct06968585-j-clin-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 T...","note":"Liu Y, Li D, Wu L, et al. Clinical lung cancer.","from":"paper-nct05246514-clin-lung-cancer-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer","note":"Loibl S, Park YH, Shao Z, et al. New England Journal of Medicine.","from":"paper-destiny-breast05-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","note":"Tolaney SM, Jiang Z, Zhang Q, et al. New England Journal of Medicine.","from":"paper-destiny-breast09-n-engl-j-med-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a mult...","note":"Yao H, Zhang Q, Li H, et al. The Lancet Oncology.","from":"paper-horizon-breast01-lancet-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer","note":"Wang S, Zhang Q, Jiang Z, et al. ESMO Open.","from":"paper-tropion-breast01-china-cohort-esmo-open-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the ra...","note":"Hurvitz SA, Loi S, O'Shaughnessy J, et al. Annals of Oncology.","from":"paper-her2climb-02-ann-oncol-2026","refs":[]},{"group":"paper","date":"2026","precision":"year","title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 +, RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis","note":"Strickler JH, Cercek A, Siena S, et al. Nature Communications.","from":"paper-mountaineer-nat-commun-2026-update","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Cardio-oncology: the Polish National Oncology Network model","note":"European Heart Journal","from":"beata-jagielska","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-m...","note":"Lancet Oncology","from":"david-sebag-montefiore","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Comparative analysis of BRCA pathogenic variant detection in a real-world setting: population screening versus oncogenetic clinics","note":"JCO Precision Oncology","from":"ephrat-levy-lahad","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Dual checkpoint blockade beyond clinical trials: real-world experience with nivolumab and ipilimumab","from":"gal-markel","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endome...","note":"Gynecologic Oncology","from":"matthew-powell","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"From evidence to action: the IARC’s role in strengthening cancer prevention and early detection","note":"JNCI Monographs","from":"basu-partha","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Impact of Early versus Delayed G-CSF Administration on Clinical Outcomes in Chemotherapy-induced Neutropenia: A Propensity Score-matching Cohort Study","note":"Journal of Cancer Research and Practice","from":"nei-min-chu","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partner...","note":"International Journal of Gynecological Cancer","from":"thomas-herzog","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Managing healthcare for female BRCA carriers in the population screening era: developing a harmonized national policy for surveillance and risk-reduction","note":"Israel Journal of Health Policy Research","from":"rachel-michaelson-cohen","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Mapping intratumor heterogeneity across layers for advancing immunotherapy","note":"Cell","from":"yardena-samuels","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Mechanisms of ubiquitylation of the mitotic regulatory protein Cdc20","from":"avram-hershko","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Native elution immunoaffinity chromatography for the efficient purification of vesicular stomatitis virus","note":"Journal of Chromatography A","from":"beata-halassy","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients...","note":"European Journal of Cancer","from":"elena-garralda","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection","note":"International Journal of Cancer","from":"ramon-salazar-soler","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Proteolysis targeting chimeric-based technology in myeloma and lymphoma","from":"aaron-ciechanover","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis","note":"eBioMedicine","from":"paul-boutros","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: outcomes from the European Registry of Hereditary Pancreati...","note":"European Journal of Cancer","from":"chris-halloran","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Sex differences in the cancer proteome","note":"BMJ Oncology","from":"paul-boutros","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mechanisms of resistance","from":"yosef-yarden","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"The Landscape of Prostate Tumor Methylation","note":"Cancer Discovery","from":"paul-boutros","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"The landscape of the ubiquitin-proteasome system in cancer","from":"aaron-ciechanover","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens","from":"yosef-yarden","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Translational recoding in tumors","note":"Cold Spring Harbor Perspectives in Biology","from":"yardena-samuels","refs":[]},{"group":"person-paper","date":"2026","precision":"year","title":"Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma","note":"Gastroenterology","from":"diane-simeone","refs":[]},{"group":"regulatory","date":"2026","precision":"year","title":"Cretostimogene grenadenorepvec: filing (US)","note":"Rolling BLA initiated; completion expected Q4 2026","from":"cretostimogene","refs":[]},{"group":"regulatory","date":"2026","precision":"year","title":"Fianlimab: designation (US)","note":"First-line metastatic phase 3 missed its primary PFS endpoint (Regeneron release)","from":"fianlimab","refs":[]},{"group":"technology","date":"2026","precision":"year","title":"PROTACs & molecular glues (targeted protein degradation)","note":"First use in humans or first approval, as the technology record states it.","from":"protac-degrader","refs":[]},{"group":"trial","date":"2026","precision":"year","title":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus  reported","from":"nct05609370","refs":["colorectal","tislelizumab"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer reported","from":"nct05608044","refs":["colorectal","botensilimab"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Posit...","from":"nct05673785","refs":["non-hodgkin-lymphoma","peripheral-t-cell-lymphoma","brentuximab-vedotin","cyclophosphamide"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR) reported","from":"nct05388669","refs":["nsclc","sclc","egfr-mutant-nsclc","lazertinib"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Del...","from":"nct04497844","refs":["prostate","prostate-mhspc","abiraterone","niraparib"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma reported","from":"nct04194775","refs":["hcc","hcc-advanced","lenvatinib"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer reported","from":"nct03742102","refs":["tnbc","tnbc-metastatic","durvalumab","capivasertib"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors reported","from":"nct03899792","refs":["thyroid","sarcoma","selpercatinib"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S reported","from":"nct04351555","refs":["nsclc","sclc","resectable-nsclc","osimertinib"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol reported","from":"nct06099782","refs":["nsclc","sclc","rcc","melanoma"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET reported","note":"Objective response 64 percent after platinum chemotherapy and 85 percent in previously untreated RET fusion-positive non-small-cell lung cancer; intracranial response 91 percent.","from":"nct03157128","refs":["nsclc","sclc","thyroid","ret-fusion-nsclc"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma reported","from":"nct05625399","refs":["melanoma","advanced-melanoma","nivolumab","relatlimab-nivolumab"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance reported","from":"nct04810078","refs":["rcc","clear-cell-rcc","nivolumab"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors reported","from":"nct06390995","refs":["ovarian","mirvetuximab-soravtansine"]},{"group":"trial","date":"2026","precision":"year","title":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley...","from":"nct05327530","refs":["urothelial","muscle-invasive-bladder-cancer","avelumab","sacituzumab-govitecan"]},{"group":"trial","date":"2026","precision":"year","title":"A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib reported","from":"nct03744715","refs":["breast-cancer","poziotinib"]},{"group":"trial","date":"2026","precision":"year","title":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Particip...","from":"nct05197426","refs":["aml","azacitidine"]},{"group":"trial","date":"2026","precision":"year","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple reported","from":"nct02773030","refs":["multiple-myeloma","iberdomide","dexamethasone","daratumumab"]},{"group":"trial","date":"2026","precision":"year","title":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) reported","from":"nct04765059","refs":["nsclc","sclc","osimertinib"]},{"group":"trial","date":"2026","precision":"year","title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) reported","from":"nct04225117","refs":["metastatic-cancer","enfortumab-vedotin","pembrolizumab"]},{"group":"trial","date":"2026","precision":"year","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHO...","from":"nct04980222","refs":["non-hodgkin-lymphoma","dlbcl","glofitamab","tocilizumab"]},{"group":"trial","date":"2026","precision":"year","title":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed reported","from":"nct06101134","refs":["melanoma","nivolumab","relatlimab-nivolumab"]},{"group":"trial","date":"2026","precision":"year","title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Phila...","from":"nct05456191","refs":["cml","cml-chronic-phase","asciminib","nilotinib"]},{"group":"trial","date":"2026","precision":"year","title":"ALTAIR reported","note":"Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.","from":"altair","refs":["colorectal","trifluridine-tipiracil","signatera"]},{"group":"trial","date":"2026","precision":"year","title":"AMPLIFY-7P reported","note":"Primary DFS endpoint not met.","from":"amplify-7p","refs":["pancreatic","resectable-pdac","eli-002-7p"]},{"group":"trial","date":"2026","precision":"year","title":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi reported","from":"nct04717414","refs":["myeloproliferative-neoplasms","primary-myelofibrosis","luspatercept"]},{"group":"trial","date":"2026","precision":"year","title":"ASCERTAIN-V reported","note":"CR 41.6%; median time to CR 2 months.","from":"ascertain-v","refs":["aml","decitabine-cedazuridine","venetoclax"]},{"group":"trial","date":"2026","precision":"year","title":"AZUR-1 reported","note":"Primary endpoint (sustained cCR at 12 months) met; rates pending congress presentation.","from":"azur-1","refs":["colorectal","msi-high-colorectal","rectal-cancer","dostarlimab"]},{"group":"trial","date":"2026","precision":"year","title":"BL-B01D1-307 reported","note":"PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).","from":"bl-b01d1-307","refs":["tnbc","izalontamab-brengitecan"]},{"group":"trial","date":"2026","precision":"year","title":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma reported","from":"nct05440786","refs":["ewing-sarcoma","abemaciclib","temozolomide"]},{"group":"trial","date":"2026","precision":"year","title":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC reported","note":"Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).","from":"nct03997123","refs":["tnbc","tnbc-metastatic","capivasertib","paclitaxel"]},{"group":"trial","date":"2026","precision":"year","title":"CLARITY-Gastric 01 reported","note":"Co-primary endpoints including OS met (July 2026); numbers pending.","from":"clarity-gastric01","refs":["gastric","cmg901","ramucirumab"]},{"group":"trial","date":"2026","precision":"year","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) reported","note":"At the final analysis (median follow-up 38.5 months) overall survival favoured perioperative tislelizumab (hazard ratio 0.65, 95 percent confidence interval 0.45 to 0.93, p=0.009)...","from":"nct04379635","refs":["nsclc","sclc","resectable-nsclc","tislelizumab"]},{"group":"trial","date":"2026","precision":"year","title":"DeLLphi-305 reported","note":"Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not ye...","from":"dellphi-305","refs":["sclc","extensive-stage-sclc","tarlatamab","durvalumab"]},{"group":"trial","date":"2026","precision":"year","title":"DREAM3R reported","note":"Stopped early; primary endpoint not met.","from":"dream3r","refs":["mesothelioma","durvalumab","pemetrexed"]},{"group":"trial","date":"2026","precision":"year","title":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination D...","from":"nct03742895","refs":["metastatic-cancer","olaparib"]},{"group":"trial","date":"2026","precision":"year","title":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cance...","from":"nct04655976","refs":["nsclc","cobolimab"]},{"group":"trial","date":"2026","precision":"year","title":"EMERALD-3 reported","note":"PFS HR ~0.70 (interim); OS immature.","from":"emerald-3","refs":["hcc","hcc-intermediate","durvalumab","tremelimumab"]},{"group":"trial","date":"2026","precision":"year","title":"EPCORE DLBCL-1 reported","note":"PFS HR 0.74; OS HR 0.96 (NS).","from":"epcore-dlbcl-1","refs":["dlbcl","epcoritamab"]},{"group":"trial","date":"2026","precision":"year","title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H)  reported","from":"nct04895722","refs":["colorectal","msi-high-colorectal","pembrolizumab","favezelimab"]},{"group":"trial","date":"2026","precision":"year","title":"Fianlimab + cemiplimab phase 3 (first-line melanoma) reported","note":"Primary PFS endpoint not met; numerical +5.1 months median PFS at the high dose.","from":"fianlimab-phase3-melanoma","refs":["melanoma","advanced-melanoma","fianlimab","cemiplimab"]},{"group":"trial","date":"2026","precision":"year","title":"FIGHT-302 reported","from":"fight-302","refs":["cholangiocarcinoma","intrahepatic-cholangiocarcinoma","biliary-tract-cancer","pemigatinib"]},{"group":"trial","date":"2026","precision":"year","title":"FOURLIGHT-1 reported","note":"PFS improved (HR not yet published in detail).","from":"fourlight-1","refs":["breast-hr-positive","atirmociclib"]},{"group":"trial","date":"2026","precision":"year","title":"GeparDouze / NSABP B-59 reported","note":"EFS HR 0.80 (0.62 to 1.03), p 0.083, not significant; OS HR 0.86 (0.62 to 1.19).","from":"gepardouze","refs":["tnbc","tnbc-early","atezolizumab","carboplatin"]},{"group":"trial","date":"2026","precision":"year","title":"HARMONi-3 reported","note":"Interim PFS not statistically significant (May 2026); final readouts pending.","from":"harmoni-3","refs":["nsclc","pdl1-high-nsclc","ivonescimab","pembrolizumab"]},{"group":"trial","date":"2026","precision":"year","title":"HERIZON-GEA-01 reported","note":"PFS 12.4 vs 8.1 months (HR 0.63-0.65); OS significantly improved.","from":"herizon-gea-01","refs":["gastric","esophageal","zanidatamab","trastuzumab"]},{"group":"trial","date":"2026","precision":"year","title":"INTerpath-001 (V940-001) reported","note":"RFS and DMFS significantly improved (HRs pending presentation).","from":"interpath-001","refs":["melanoma","stage-iii-melanoma","stage-ii-melanoma","intismeran-autogene"]},{"group":"trial","date":"2026","precision":"year","title":"Krascendo 1 reported","note":"Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).","from":"krascendo-1","refs":["nsclc","kras-g12c-nsclc","divarasib","sotorasib"]},{"group":"trial","date":"2026","precision":"year","title":"LITESPARK-011 reported","note":"Final progression-free survival 14.8 vs 10.7 months (hazard ratio 0.70, 95% CI 0.59 to 0.84; one-sided p<0.0001).","from":"nct04586231","refs":["rcc","belzutifan","lenvatinib","cabozantinib"]},{"group":"trial","date":"2026","precision":"year","title":"LITESPARK-012 reported","note":"Primary endpoint not met (ASCO GU 2026).","from":"litespark-012","refs":["rcc","belzutifan","lenvatinib","pembrolizumab"]},{"group":"trial","date":"2026","precision":"year","title":"LITESPARK-022 reported","note":"DFS significantly improved vs pembrolizumab (interim; HR presented ASCO GU 2026).","from":"litespark-022","refs":["rcc","belzutifan","pembrolizumab"]},{"group":"trial","date":"2026","precision":"year","title":"MATRix/IELSG43 reported","note":"Three-year progression-free survival 78 percent after high-dose chemotherapy and autologous transplant against 51 percent after non-myeloablative R-DeVIC (hazard ratio 0.43, p 0.00...","from":"ielsg43","refs":["primary-cns-lymphoma","non-hodgkin-lymphoma","brain-tumours","thiotepa"]},{"group":"trial","date":"2026","precision":"year","title":"METRO PLUS (Tata Memorial Centre, Varanasi) reported","note":"Median OS 10 vs 5 months, HR 0.54.","from":"metro-plus-varanasi","refs":["head-and-neck","recurrent-metastatic-hnscc","buccal-mucosa-cancer","paclitaxel"]},{"group":"trial","date":"2026","precision":"year","title":"NHS-Galleri reported","from":"nhs-galleri","refs":["lung-cancer","head-and-neck","colorectal","pancreatic"]},{"group":"trial","date":"2026","precision":"year","title":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations reported","from":"nct04042831","refs":["gallbladder","cholangiocarcinoma","biliary-tract-cancer","olaparib"]},{"group":"trial","date":"2026","precision":"year","title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib reported","from":"nct03778229","refs":["metastatic-cancer","egfr-mutant-nsclc","met-altered-nsclc","osimertinib"]},{"group":"trial","date":"2026","precision":"year","title":"PANKU-Esophagus01 (BL-B01D1-305) reported","note":"OS and PFS significantly improved at interim analysis; numbers per ASCO 2026 presentation.","from":"panku-esophagus01","refs":["esophageal","izalontamab-brengitecan"]},{"group":"trial","date":"2026","precision":"year","title":"PEACE-3 (EORTC 1333) reported","note":"Median overall survival 38.2 months with enzalutamide plus radium-223 against 32.6 months with enzalutamide alone (hazard ratio 0.76, 95 percent confidence interval 0.60 to 0.96, p...","from":"peace-3","refs":["prostate","prostate-mcrpc","radium-223","enzalutamide"]},{"group":"trial","date":"2026","precision":"year","title":"persevERA reported","note":"PFS 33.1 vs 28.2 months, not significant.","from":"persevera","refs":["breast-hr-positive","giredestrant","palbociclib"]},{"group":"trial","date":"2026","precision":"year","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) reported","from":"nct04793958","refs":["colorectal","kras-g12c-colorectal","cetuximab"]},{"group":"trial","date":"2026","precision":"year","title":"RASolute 302 reported","note":"OS 13.2 vs 6.7 months, HR 0.40.","from":"rasolute-302","refs":["pancreatic","metastatic-pdac","daraxonrasib"]},{"group":"trial","date":"2026","precision":"year","title":"STAR-TREC reported","from":"star-trec","refs":["colorectal","rectal-cancer"]},{"group":"trial","date":"2026","precision":"year","title":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment reported","from":"nct06502977","refs":["sclc","tarlatamab"]},{"group":"trial","date":"2026","precision":"year","title":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma reported","from":"nct05471843","refs":["mantle-cell-lymphoma","sonrotoclax"]},{"group":"trial","date":"2026","precision":"year","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto reported","from":"nct04940052","refs":["thyroid","dabrafenib","trametinib"]},{"group":"trial","date":"2026","precision":"year","title":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN reported","from":"nct03386513","refs":["bpdcn","myeloproliferative-neoplasms","pivekimab-sunirine"]},{"group":"trial","date":"2026","precision":"year","title":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) reported","from":"nct05804045","refs":["tenosynovial-giant-cell-tumour"]},{"group":"trial","date":"2026","precision":"year","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastati...","from":"nct05287113","refs":["head-and-neck","recurrent-metastatic-hnscc","retifanlimab"]},{"group":"trial","date":"2026","precision":"year","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS reported","note":"Second-line daraxonrasib 300 mg in 26 patients with RAS G12-mutated pancreatic cancer: objective response 35 percent, median progression-free survival 8.5 months, median overall su...","from":"nct05379985","refs":["nsclc","sclc","colorectal","pancreatic"]},{"group":"trial","date":"2026","precision":"year","title":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors reported","from":"nct03964727","refs":["metastatic-cancer","sacituzumab-govitecan"]},{"group":"trial","date":"2026","precision":"year","title":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy reported","from":"nct05583552","refs":["mds","aml","mds-higher-risk","imetelstat"]},{"group":"trial","date":"2026","precision":"year","title":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi reported","from":"nct07150104","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin","nirogacestat"]},{"group":"trial","date":"2026","precision":"year","title":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM reported","from":"nct07217119","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin","feladilimab"]},{"group":"trial","date":"2026","precision":"year","title":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM reported","from":"nct07217184","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin","isatuximab"]},{"group":"trial","date":"2026","precision":"year","title":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM reported","from":"nct07084896","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin","nirogacestat"]},{"group":"trial","date":"2026","precision":"year","title":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM reported","from":"nct07150091","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin","nirogacestat"]},{"group":"trial","date":"2026","precision":"year","title":"TRANSCEND reported","note":"Least-squares mean change in body-mass index at 52 weeks minus 16.5% with setmelanotide vs plus 3.3% with placebo (P<0.001); hunger score change minus 2.73 vs minus 1.45 (P = 0.009...","from":"transcend","refs":["craniopharyngioma","setmelanotide"]},{"group":"trial","date":"2026","precision":"year","title":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer reported","from":"nct04094688","refs":["rectal-cancer","colon-cancer","bevacizumab-glioma","folfox"]},{"group":"trial","date":"2026","precision":"year","title":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083 reported","note":"Primary PFS endpoint not met; mPFS 12.75 vs 7.43 months (mITT) not significant.","from":"xport-ec-042","refs":["endometrial","advanced-recurrent-endometrial-cancer","endometrial-nsmp","selinexor"]},{"group":"regulatory","date":"2026-01","precision":"month","title":"Ivonescimab: filing (US)","note":"BLA submitted by Summit for EGFR-mutant NSCLC after TKI (HARMONi)","from":"ivonescimab","refs":[]},{"group":"regulatory","date":"2026-01-16","precision":"day","title":"Epcoritamab: filing (US)","note":"EPCORE DLBCL-1 topline: PFS met, OS (US primary endpoint) not met","from":"epcoritamab","refs":[]},{"group":"regulatory","date":"2026-01-29","precision":"day","title":"Galleri: filing (US)","note":"Final PMA module submitted","from":"galleri","refs":[]},{"group":"regulatory","date":"2026-01-30","precision":"day","title":"Camrelizumab + rivoceranib: filing (US)","note":"Resubmission accepted; PDUFA 23 July 2026","from":"camrelizumab-rivoceranib","refs":[]},{"group":"regulatory","date":"2026-02","precision":"month","title":"Anitocabtagene autoleucel: filing (US)","note":"BLA accepted; PDUFA 27 December 2026","from":"anitocabtagene-autoleucel","refs":[]},{"group":"regulatory","date":"2026-02","precision":"month","title":"Atirmociclib: designation (Global)","note":"Positive topline phase 2 FOURLIGHT-1","from":"atirmociclib","refs":[]},{"group":"regulatory","date":"2026-02-19","precision":"day","title":"Acalabrutinib: approval (US)","note":"Acalabrutinib + venetoclax fixed duration (AMPLIFY)","from":"acalabrutinib","refs":[]},{"group":"regulatory","date":"2026-02-19","precision":"day","title":"Giredestrant: filing (US)","note":"NDA accepted (evERA, ESR1-mutant)","from":"giredestrant","refs":[]},{"group":"regulatory","date":"2026-02-26","precision":"day","title":"Izalontamab brengitecan: filing (China)","note":"Positive interim phase 3 in pretreated TNBC (BL-B01D1-307) announced; regulatory submissions follow","from":"izalontamab-brengitecan","refs":[]},{"group":"guideline","date":"2026-03","precision":"month","title":"NCCN 2026 update for HER2-positive breast cancer","note":"1 row recategorised. Anchored to Approval of trastuzumab deruxtecan for residual disease after neoadjuvant therapy, 2026 (DESTINY-Breast05).","from":"breast-her2-positive","refs":["trastuzumab-deruxtecan","trastuzumab-emtansine","destiny-breast05","katherine"]},{"group":"regulatory","date":"2026-03","precision":"month","title":"Nivolumab: approval (US)","note":"First-line advanced classical Hodgkin lymphoma with AVD, age ≥12 (SWOG S1826)","from":"nivolumab","refs":[]},{"group":"regulatory","date":"2026-03","precision":"month","title":"Tafasitamab: filing (US)","note":"sBLA for frontline high-risk DLBCL (frontMIND) planned H1 2026","from":"tafasitamab","refs":[]},{"group":"regulatory","date":"2026-03","precision":"month","title":"Tazemetostat: withdrawal (Global)","note":"Withdrawn over secondary haematologic malignancies","from":"tazemetostat","refs":[]},{"group":"regulatory","date":"2026-03","precision":"month","title":"Zelenectide pevedotin: withdrawal (US)","note":"Programme deprioritised after regulatory feedback on Duravelo-2 design","from":"zelenectide-pevedotin","refs":[]},{"group":"regulatory","date":"2026-03-05","precision":"day","title":"Daratumumab: approval (US)","note":"Teclistamab + daratumumab after ≥1 prior line","from":"daratumumab","refs":[]},{"group":"regulatory","date":"2026-03-09","precision":"day","title":"Giredestrant: designation (Global)","note":"persevERA primary endpoint not met","from":"giredestrant","refs":[]},{"group":"regulatory","date":"2026-03-09","precision":"day","title":"Piflufolastat F-18 / Pylarify TruVu: approval (US)","note":"Pylarify TruVu formulation","from":"pylarify","refs":[]},{"group":"expected","date":"2026-03-16","precision":"day","title":"CAPItello-290 study completion on the registry (capivasertib plus paclitaxel first line; published negative for overall survival in 2026)","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["nct03997123","capivasertib","paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026"]},{"group":"regulatory","date":"2026-04-30","precision":"day","title":"Camizestrant: advisory committee (US)","note":"ODAC voted 6-3 against (clinical relevance of ctDNA-triggered switch)","from":"camizestrant","refs":[]},{"group":"regulatory","date":"2026-05","precision":"month","title":"ArteraAI Breast: approval (US)","note":"FDA clearance: first digital-pathology-based risk stratification tool for early HR+/HER2- breast cancer","from":"artera-ai-breast","refs":[]},{"group":"regulatory","date":"2026-05-13","precision":"day","title":"Decitabine + cedazuridine (oral): approval (US)","note":"With venetoclax in newly diagnosed unfit AML","from":"decitabine-cedazuridine","refs":[]},{"group":"regulatory","date":"2026-05-13","precision":"day","title":"Sonrotoclax: approval (US)","note":"Accelerated approval in MCL; priority review, Project Orbis","from":"sonrotoclax","refs":[]},{"group":"regulatory","date":"2026-05-22","precision":"day","title":"Datopotamab deruxtecan: approval (US)","note":"First-line unresectable/metastatic TNBC, PD-1/PD-L1 inhibitor ineligible (TROPION-Breast02)","from":"datopotamab-deruxtecan","refs":[]},{"group":"regulatory","date":"2026-05-27","precision":"day","title":"Pivekimab sunirine: approval (US)","note":"FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy","from":"pivekimab-sunirine","refs":[]},{"group":"regulatory","date":"2026-05-28","precision":"day","title":"Durvalumab: approval (US)","note":"High-risk non-muscle-invasive bladder cancer with BCG (POTOMAC)","from":"durvalumab","refs":[]},{"group":"expected","date":"2026-06","precision":"month","title":"NordICC primary completion on the registry (colonoscopy screening, 95,000 participants, actual; active, not recruiting); study completion is listed as July 2036...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["nordicc","colorectal-screening","idea-crc-screening-uptake-and-age-extension"]},{"group":"expected","date":"2026-06","precision":"month","title":"RASolute 302 primary completion on the registry (daraxonrasib versus chemotherapy, previously treated metastatic disease, 500 participants, actual; published an...","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["rasolute-302","daraxonrasib","paper-daraxonrasib-pancreatic-n-engl-j-med-2026"]},{"group":"regulatory","date":"2026-06-12","precision":"day","title":"Belzutifan: approval (US)","note":"Adjuvant clear-cell RCC with pembrolizumab (LITESPARK-022)","from":"belzutifan","refs":[]},{"group":"regulatory","date":"2026-06-12","precision":"day","title":"Capivasertib: approval (US)","note":"PTEN-deficient metastatic prostate cancer with abiraterone (CAPItello-281)","from":"capivasertib","refs":[]},{"group":"regulatory","date":"2026-06-12","precision":"day","title":"Pembrolizumab: approval (US)","note":"Adjuvant RCC with belzutifan (LITESPARK-022)","from":"pembrolizumab","refs":[]},{"group":"regulatory","date":"2026-06-12","precision":"day","title":"Prednisone: approval (US)","note":"FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer","from":"prednisone","refs":[]},{"group":"expected","date":"2026-06-21","precision":"day","title":"COBRA (NRG-GI005) study completion: circulating tumour DNA testing to direct treatment in stage IIA colon cancer (635 participants, actual; active, not recruiti...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["mrd-testing","ctdna","idea-crc-ctdna-de-escalation-beyond-stage-ii"]},{"group":"regulatory","date":"2026-06-24","precision":"day","title":"Palbociclib: approval (US)","note":"Maintenance in HR+/HER2+ advanced breast cancer with anti-HER2 and endocrine therapy (PATINA)","from":"palbociclib","refs":[]},{"group":"regulatory","date":"2026-06-24","precision":"day","title":"Pembrolizumab: approval (US)","note":"First-line PD-L1+ TNBC with sacituzumab govitecan (ASCENT-04)","from":"pembrolizumab","refs":[]},{"group":"regulatory","date":"2026-06-24","precision":"day","title":"Pertuzumab: approval (US)","note":"FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer","from":"pertuzumab","refs":[]},{"group":"regulatory","date":"2026-06-24","precision":"day","title":"Sacituzumab govitecan: approval (US)","note":"First-line metastatic TNBC: monotherapy (PD-1 ineligible, ASCENT-03) and with pembrolizumab (CPS ≥10, ASCENT-04)","from":"sacituzumab-govitecan","refs":[]},{"group":"regulatory","date":"2026-06-24","precision":"day","title":"Trastuzumab: approval (US)","note":"FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer","from":"trastuzumab","refs":[]},{"group":"regulatory","date":"2026-06-25","precision":"day","title":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes): complete response letter (EU)","note":"CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute","from":"tacquell","refs":[]},{"group":"regulatory","date":"2026-06-30","precision":"day","title":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq: approval (US)","note":"FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq (Tregzi, Orca Bio) on the Precision-T trial","from":"tregzi","refs":[]},{"group":"regulatory","date":"2026-07","precision":"month","title":"Isatuximab: approval (US)","note":"Subcutaneous on-body injector","from":"isatuximab","refs":[]},{"group":"regulatory","date":"2026-07","precision":"month","title":"Sacituzumab tirumotecan: designation (US)","note":"Commissioner's National Priority Voucher (CNPV) awarded","from":"sacituzumab-tirumotecan","refs":[]},{"group":"regulatory","date":"2026-07-09","precision":"day","title":"Isatuximab: approval (US)","note":"FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications","from":"isatuximab","refs":[]},{"group":"regulatory","date":"2026-07-10","precision":"day","title":"Enfortumab vedotin: approval (US)","note":"Muscle-invasive bladder cancer with pembrolizumab, with or without berahyaluronidase alfa","from":"enfortumab-vedotin","refs":[]},{"group":"regulatory","date":"2026-07-10","precision":"day","title":"Pembrolizumab: approval (US)","note":"Muscle-invasive bladder cancer with enfortumab vedotin, as pembrolizumab or pembrolizumab with berahyaluronidase alfa","from":"pembrolizumab","refs":[]},{"group":"regulatory","date":"2026-07-14","precision":"day","title":"Fulvestrant: approval (US)","note":"FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer","from":"fulvestrant","refs":[]},{"group":"regulatory","date":"2026-07-14","precision":"day","title":"Gedatolisib: approval (US)","note":"HR+/HER2- advanced breast cancer after CDK4/6 inhibitor with palbociclib and fulvestrant (VIKTORIA-1)","from":"gedatolisib","refs":[]},{"group":"regulatory","date":"2026-07-14","precision":"day","title":"Palbociclib: approval (US)","note":"Gedatolisib with fulvestrant, with or without palbociclib, HR+/HER2- advanced breast cancer (VIKTORIA-1)","from":"palbociclib","refs":[]},{"group":"regulatory","date":"2026-07-14","precision":"day","title":"Selpercatinib: approval (US)","note":"Traditional approval, locally advanced or metastatic RET fusion-positive solid tumours","from":"selpercatinib","refs":[]},{"group":"regulatory","date":"2026-07-17","precision":"day","title":"Daraxonrasib: filing (US)","note":"NDA 220910 received by the FDA on the RASolute 302 result","from":"daraxonrasib","refs":[]},{"group":"regulatory","date":"2026-07-22","precision":"day","title":"Zidesamtinib: approval (US)","note":"ROS1+ NSCLC after at least one prior ROS1 TKI (ARROS-1)","from":"zidesamtinib","refs":[]},{"group":"regulatory","date":"2026-07-23","precision":"day","title":"Camrelizumab + rivoceranib: complete response letter (US)","note":"Third CRL, again cGMP","from":"camrelizumab-rivoceranib","refs":[]},{"group":"expected","date":"2026-07-30","precision":"day","title":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma: primary completion","note":"Actual primary completion date on ClinicalTrials.gov.","from":"nct04724369","refs":[]},{"group":"regulatory","date":"2026-07-30","precision":"day","title":"Selinexor: filing (US)","note":"XPORT-EC-042 misses primary endpoint; endometrial development deprioritised","from":"selinexor","refs":[]},{"group":"regulatory","date":"2026-07-31","precision":"day","title":"Lutetium-177 vipivotide tetraxetan: approval (US)","note":"PSMA+ metastatic hormone-sensitive prostate cancer with ARPI (PSMAddition)","from":"pluvicto","refs":[]},{"group":"regulatory","date":"2026-08-06","precision":"day","title":"Nivolumab: approval (US)","note":"Accelerated approval of vusolimogene oderparepvec in combination with nivolumab, unresectable advanced cutaneous melanoma","from":"nivolumab","refs":[]},{"group":"regulatory","date":"2026-08-06","precision":"day","title":"Vusolimogene oderparepvec: approval (US)","note":"Accelerated approval with nivolumab for unresectable/metastatic melanoma after anti-PD-1 (IGNYTE)","from":"vusolimogene-oderparepvec","refs":[]},{"group":"regulatory","date":"2026-08-13","precision":"day","title":"Daratumumab: approval (US)","note":"FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma","from":"daratumumab","refs":[]},{"group":"regulatory","date":"2026-08-13","precision":"day","title":"Dexamethasone: approval (US)","note":"FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma","from":"dexamethasone","refs":[]},{"group":"regulatory","date":"2026-08-13","precision":"day","title":"Iberdomide: approval (US)","note":"FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma","from":"iberdomide","refs":[]},{"group":"regulatory","date":"2026-08-19","precision":"day","title":"Intismeran autogene: filing (US)","note":"Phase 3 INTerpath-001 met RFS and DMFS endpoints; filings to follow","from":"intismeran-autogene","refs":[]},{"group":"expected","date":"2026-08-20","precision":"day","title":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome: primary completion","note":"Actual primary completion date on ClinicalTrials.gov.","from":"nct06050122","refs":[]},{"group":"regulatory","date":"2026-08-25","precision":"day","title":"Tislelizumab: approval (US)","note":"FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma","from":"tislelizumab","refs":[]},{"group":"regulatory","date":"2026-08-25","precision":"day","title":"Zanidatamab: approval (US)","note":"First-line HER2-positive gastric, gastro-oesophageal junction or oesophageal adenocarcinoma with tislelizumab and fluoropyrimidine-platinum chemotherapy","from":"zanidatamab","refs":[]},{"group":"regulatory","date":"2026-08-26","precision":"day","title":"Daraxonrasib: approval (US)","note":"NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent sys...","from":"daraxonrasib","refs":[]},{"group":"regulatory","date":"2026-08-28","precision":"day","title":"177Lu-edotreotide: decision date set (US)","note":"PDUFA goal date for GEP-NET indication","from":"itm-11","refs":[]},{"group":"regulatory","date":"2026-09-04","precision":"day","title":"Camizestrant: approval (US)","note":"Accelerated approval (Etcamah)","from":"camizestrant","refs":[]},{"group":"regulatory","date":"2026-09-09","precision":"day","title":"Sevabertinib: approval (US)","note":"FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer","from":"sevabertinib","refs":[]},{"group":"expected","date":"2026-09-18","precision":"day","title":"FDA decision: zidesamtinib in TKI-pretreated ROS1-positive NSCLC","note":"Confirmed date. PDUFA target action date stated by Nuvalent when the FDA accepted the new drug application. Nuvalent's first potential approval.","from":"zidesamtinib","refs":["nuvalent","ros1","nsclc"]},{"group":"expected","date":"2026-09-22","precision":"day","title":"NHS-Galleri: peer-reviewed test-performance paper (reported: Nature Medicine, 22 September 2026, states the primary endpoint was not met and is reported elsewhe...","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["nhs-galleri","galleri","stage-shift","paper-nhs-galleri-performance-nat-med-2026"]},{"group":"expected","date":"2026-09-23","precision":"day","title":"FDA advisory committee: Galleri multi-cancer early detection test (PMA)","note":"Confirmed date. Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee reviews GRAIL's premarket approval application.","from":"galleri","refs":["grail","mced","nhs-galleri","pathfinder-2"]},{"group":"expected","date":"2026-09-23","precision":"day","title":"FDA Molecular and Clinical Genetics Panel reviews the Galleri premarket approval application","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["galleri","grail","mced"]},{"group":"regulatory","date":"2026-09-23","precision":"day","title":"Galleri: advisory committee (US)","note":"FDA Molecular and Clinical Genetics Panel meeting","from":"galleri","refs":[]},{"group":"expected","date":"2026-09-30","precision":"day","title":"JANUS primary completion: adding irinotecan to FOLFOX after long-course radiotherapy in locally advanced rectal cancer (760 participants, actual; active, not re...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["rectal-cancer","irinotecan","total-neoadjuvant-therapy","idea-crc-organ-preservation-randomised-in-pmmr-rectal"]},{"group":"expected","date":"2026-10-01","precision":"day","title":"IMvigor011 study completion on the registry; longer follow-up of ctDNA-negative patients under surveillance","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["imvigor011","atezolizumab"]},{"group":"expected","date":"2026-10-23","precision":"day","title":"ESMO Congress 2026, Madrid (23 to 27 October)","note":"Confirmed date. Europe's largest oncology congress. Watch for: TROPION-Breast05, first-line ADC + IO data, late-breaking radioligand and bispecific ADC results.","from":"esmo","refs":[]},{"group":"expected","date":"2026-11","precision":"month","title":"AMPLIFY-7P study completion (ELI-002 7P adjuvant KRAS vaccine, 158 participants; primary completion 20 April 2026, actual)","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["amplify-7p","eli-002-7p","shared-antigen-vaccine"]},{"group":"expected","date":"2026-11-02","precision":"day","title":"AZUR-1 primary completion: dostarlimab monotherapy in untreated mismatch repair-deficient locally advanced rectal cancer (154 participants, actual; active, not...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["azur-1","dostarlimab","organ-preservation","msi-high-colorectal"]},{"group":"regulatory","date":"2026-11-14","precision":"day","title":"Ivonescimab: decision date set (US)","note":"PDUFA target date","from":"ivonescimab","refs":[]},{"group":"expected","date":"2026-12-08","precision":"day","title":"San Antonio Breast Cancer Symposium 2026 (8 to 11 December)","note":"Confirmed date. The breast cancer congress. Post-neoadjuvant TNBC ADC trials (ASCENT-05, TROPION-Breast03) and sac-TMT first-line TNBC data are candidates for presentation here or...","from":"tnbc","refs":["breast-hr-positive","breast-her2-positive"]},{"group":"expected","date":"2026-12-12","precision":"day","title":"ASH Annual Meeting 2026, New Orleans (12 to 15 December)","note":"Confirmed date. Haematology's main congress: CAR-T, bispecifics, menin inhibitors, BCL-2 combinations.","from":"aml","refs":["dlbcl","multiple-myeloma","cll","all-leukemia"]},{"group":"expected","date":"2026-12-18","precision":"day","title":"ATOMIC (Alliance A021502) study completion: adjuvant FOLFOX with or without atezolizumab in stage III mismatch repair-deficient colon cancer (712 participants...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["atomic","atezolizumab","msi-high-colorectal"]},{"group":"expected","date":"2026-12-31","precision":"day","title":"TROPION-Breast02 study completion on the registry (datopotamab deruxtecan first line, immunotherapy-ineligible; primary completion 25 August 2025, actual)","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["tropion-breast02","datopotamab-deruxtecan"]},{"group":"regulatory","date":"2026-Q1","precision":"quarter","title":"Encorafenib: approval (US)","note":"Full approval in first-line BRAF V600E mCRC with OS benefit","from":"encorafenib","refs":[]},{"group":"regulatory","date":"2026-Q1","precision":"quarter","title":"Optune / Optune Pax (TTFields): approval (US)","note":"Optune Pax, locally advanced pancreatic cancer with chemotherapy (PANOVA-3)","from":"optune","refs":[]},{"group":"regulatory","date":"2026-Q1","precision":"quarter","title":"Pembrolizumab: approval (US)","note":"Platinum-resistant PD-L1+ ovarian cancer","from":"pembrolizumab","refs":[]},{"group":"regulatory","date":"2026-Q1","precision":"quarter","title":"Relacorilant: approval (US)","note":"Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel","from":"relacorilant","refs":[]},{"group":"regulatory","date":"2026-Q1","precision":"quarter","title":"Teclistamab: approval (US)","note":"Relapsed/refractory myeloma after ≥1 prior line, with daratumumab (MajesTEC-3)","from":"teclistamab","refs":[]},{"group":"regulatory","date":"2026-Q1","precision":"quarter","title":"Zongertinib: approval (US)","note":"First-line HER2-mutant non-squamous NSCLC","from":"zongertinib","refs":[]},{"group":"regulatory","date":"2026-Q2","precision":"quarter","title":"Afamitresgene autoleucel: label change (US)","note":"Label extended to patients aged 12 and older","from":"afamitresgene-autoleucel","refs":[]},{"group":"regulatory","date":"2026-Q2","precision":"quarter","title":"Atezolizumab: approval (US)","note":"Adjuvant ctDNA-positive muscle-invasive bladder cancer (IMvigor011): first ctDNA-guided indication","from":"atezolizumab","refs":[]},{"group":"regulatory","date":"2026-Q2","precision":"quarter","title":"Signatera: label change (US)","note":"Used to select ctDNA-positive patients in the first ctDNA-guided drug approval (IMvigor011, atezolizumab)","from":"signatera","refs":[]},{"group":"regulatory","date":"2026-Q2","precision":"quarter","title":"Trastuzumab deruxtecan: approval (US)","note":"Early-stage HER2+ breast cancer: neoadjuvant (DESTINY-Breast11) and post-neoadjuvant residual disease (DESTINY-Breast05)","from":"trastuzumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2026-Q2","precision":"quarter","title":"Trastuzumab emtansine: label change (US)","note":"Displaced post-neoadjuvantly by T-DXd approval (DESTINY-Breast05)","from":"trastuzumab-emtansine","refs":[]},{"group":"regulatory","date":"2026-Q2","precision":"quarter","title":"Vepdegestrant: approval (US)","note":"ESR1-mutated ER+/HER2- advanced breast cancer after endocrine therapy: first PROTAC approved","from":"vepdegestrant","refs":[]},{"group":"regulatory","date":"2026-Q2","precision":"quarter","title":"Zenocutuzumab: approval (US)","note":"NRG1-fusion cholangiocarcinoma","from":"zenocutuzumab","refs":[]},{"group":"expected","date":"2026-Q4","precision":"quarter","title":"INTerpath-001 full data: intismeran autogene + pembrolizumab, adjuvant melanoma","note":"Expected date. Topline positive 19 August 2026; hazard ratios and curves expected at a late-2026 congress (ESMO or SMR), with regulatory filings to follow.","from":"interpath-001","refs":["intismeran-autogene","melanoma"]},{"group":"expected","date":"2026-Q4","precision":"quarter","title":"NHS England decision on Galleri rollout after full NHS-Galleri results","note":"Expected date. Full results presented at ASCO 2026 (primary stage III to IV endpoint not met; stage IV reduction reported).","from":"nhs-galleri","refs":["galleri","mced"]},{"group":"expected","date":"2026-Q4","precision":"quarter","title":"Tempus completes the acquisition of Personalis","note":"Expected date. All-stock deal at $16.25 per share announced July 2026; the companies guided to a close in late 2026 or early 2027.","from":"tempus","refs":["personalis","mrd-testing","liquid-biopsy"]},{"group":"expected","date":"2026-Q4","precision":"quarter","title":"TROPION-Breast05: Dato-DXd ± durvalumab vs pembrolizumab + chemotherapy, first-line PD-L1+ TNBC","note":"Expected date. Primary completion per registry falls in 2026; timing of topline is our estimate. Would complete the ADC + IO first-line picture alongside ASCENT-04.","from":"tropion-breast05","refs":["datopotamab-deruxtecan","durvalumab","tnbc"]}]},"route":"/years/2026/","neighbours":{"year":[{"id":"2025","kind":"year","name":"2025 in oncology","route":"/years/2025/"},{"id":"2027","kind":"year","name":"2027 in oncology","route":"/years/2027/"}]}}